Electromed (ELMD) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Electromed (ELMD) has outperformed TransMedics Group (TMDX) over the past year, gaining 14.4% versus a loss of 29.6%. Over five years, TMDX leads with a +205.3% price change compared with +156.6% for ELMD. TransMedics Group is the larger company by market cap ($2.74 billion vs $230.4 million), about 11.9 times the size.
On valuation, TransMedics Group trades at a lower forward P/E (35.0x vs 45.6x for Electromed).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELMD | TMDX |
|---|---|---|
| Share price | $27.80 | $79.00 |
| Market cap | $230.38M | $2.74B |
| 1-day change | -1.42% | -2.55% |
| YTD return | -3.16% | -33.36% |
| 1-year return | +14.45% | -29.61% |
| 5-year return | +156.60% | +205.35% |
| P/E ratio (TTM) | 21.38 | 20.47 |
| Forward P/E | 45.57 | 35.05 |
| EPS (TTM) | $1.30 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $47.40 | $156.00 |
| 52-week low | $23.01 | $60.11 |
| Distance from 52-week high | -41.35% | -49.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +74.46% | +26.35% |
| Average volume | 104.76K | 815.54K |
| Shares outstanding | 8.29M | 34.68M |
| Employees | 195 | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 11.9 times larger than Electromed by market value ($2.74B vs $230.38M).
- ELMD has outperformed TMDX by 44.1 percentage points over the past year.
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
ELMD vs TMDX FAQ
Which is bigger, Electromed or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $230.38M for Electromed (ELMD).
Which stock has performed better over the past year, ELMD or TMDX?
ELMD returned +14.45% over the past 12 months, compared with -29.61% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ELMD or TMDX?
TMDX has the lower trailing P/E at 20.5, versus 21.4 for ELMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Electromed and TransMedics Group in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.